Breaking News Instant updates and real-time market news.

CTRP

Ctrip.com

$41.87

-0.39 (-0.92%)

, QUNR

Qunar

$29.95

-0.07 (-0.23%)

10:02
11/23/16
11/23
10:02
11/23/16
10:02

Ctrip, Qunar to combine vacation business divisions, Marbridge Daily reports

Ctrip (CTRP) CEO Yang Tao recently announced in an internal company-wide email that Ctrip's vacation business unit will merge with Qunar's (QUNR) vacations division, Marbridge Daily reports. Qunar's vacations business will continue to operate separately, Yang said. Qunar counts Ctrip and Baidu (BIDU) as its main shareholders. Reference Link

CTRP

Ctrip.com

$41.87

-0.39 (-0.92%)

QUNR

Qunar

$29.95

-0.07 (-0.23%)

BIDU

Baidu

$164.47

-1.22 (-0.74%)

  • 23

    Nov

CTRP Ctrip.com
$41.87

-0.39 (-0.92%)

10/25/16
GSCO
10/25/16
NO CHANGE
GSCO
Conviction Buy
Alibaba price target raised to $130 from $120 at Goldman
Goldman Sachs analyst Piyush Mubayi continues to think the outlook for organic growth rates in Alibaba's (BABA) China retail business remains robust and that the margin outlook for its core businesses is also intact. The analyst raised his price target on Alibaba shares to $130 from $120 and reiterates a Conviction List Buy rating on the stock, which remains his top pick in its sector. In the Chinese Internet space, the analyst also has Buy ratings on Tencent (TCEHY), Baidu (BIDU), JD.com (JD), Ctrip.com (CTRP), NetEase (NTES) and Vipshop (VIPS).
10/06/16
10/06/16
NO CHANGE

Ctrip.com Q3 net revenue forecast trending above guidance, says M Science
09/01/16
STFL
09/01/16
NO CHANGE
STFL
Ctrip.com price target raised to $56 from $52 at Stifel
Stifel analyst George Askew says that Ctrip.com reported "strong" results and provided "solid" revenue guidance. The analyst remains upbeat on the company's fundamentals and expects its EBITDA margins to be close to 30% in coming years. He keeps a Buy rating on the shares.
11/14/16
OPCO
11/14/16
NO CHANGE
Target $55
OPCO
Outperform
Ctrip.com pullback creates attractive buying opportunity, says Oppenheimer
Oppenheimer analyst Jed Kelly believes the recent pullback in Ctrip.com's shares creates an attractive buying opportunity. The analyst expects "solid" Q3 results, with Q4 guidance likely bracketing Street estimates. He reiterates an Outperform rating and $55 price target on the shares.
QUNR Qunar
$29.95

-0.07 (-0.23%)

06/08/16
EGHT
06/08/16
NO CHANGE
EGHT
Ctrip.com, Qunar to be hurt by airlines commission change, says 86 Research
Media reports have stated that Chinese airlines will cancel or reduce the variable portion of commissions they pay to ticketing agencies, 86 Research stated. The firm says that two major Chinese airlines have confirmed the news. 86 Research believes that the change will cripple the airline businesses of Ctrip.com (CTRP) and Qunar (QUNR). 86 Research says that Ctrip.com "lacks near-term EPS support, "but it remains positive on the company's long-term outlook. The firm recommends avoiding Qunar.
06/16/16
BMUR
06/16/16
NO CHANGE
Target $52
BMUR
Buy
Ctrip.com price target lowered to $52 from $56 at Brean Capital
Brean Capital lowered its price target on Ctrip.com (CTRP) to $52 from $56 after the company posted solid results, but provided soft guidance, which was mainly attributed to the near-term revenue growth pressure from Qunar (QUNR) given the recent adjustment of the air ticketing business and the changes to Qunar's hotel business targeting profitable growth. Brean Capital views Ctrip.com as a core holding and reiterated its Buy rating on its shares.
06/16/16
LYON
06/16/16
UPGRADE
LYON
Underperform
Qunar upgraded to Underperform from Sell at CLSA (pre-open)
08/17/16
OPCO
08/17/16
NO CHANGE
Target $55
OPCO
Outperform
Ctrip.com should be bought on any near-term weakness, says Oppenheimer
Oppenheimer analyst Jed Kelly believes Ctrip.com (CTRP) will likely beat Wall Street's Q2 revenue and margin estimates given a stable travel environment. However, the analyst says that increasing competition, and Qunar's (QUNR) ongoing China Southern dispute, could produce cautious commentary around Q3 profit and cause volatility in the shares. Nonetheless, Kelly sees Ctrip.com as well positioned to gain share of China's under-penetrated online travel market, and would take advantage of any near-term weakness to accumulate shares. He reiterates an Outperform rating and $55 price target on Ctrip.com's shares.
BIDU Baidu
$164.47

-1.22 (-0.74%)

10/28/16
FBCO
10/28/16
DOWNGRADE
FBCO
Neutral
Baidu downgraded to Neutral from Outperform at Credit Suisse
10/28/16
PIPR
10/28/16
NO CHANGE
Target $190
PIPR
Overweight
Baidu price target raised to $190 from $180 at Piper Jaffray
Piper Jaffray analyst Gene Munster raised his price target for Baidu to $190 following the company's Q3 results. The quarter and outlook show the continued impact from quality adjustments, but Q4 should mark the bottom, Munster tells investors in a post-earnings research note. He remains a long-term believer in Baidu and keeps an Overweight rating on the shares.
10/28/16
MACQ
10/28/16
DOWNGRADE
MACQ
Neutral
Baidu downgraded to Neutral from Outperform at Macquarie
10/31/16
OPCO
10/31/16
NO CHANGE
Target $200
OPCO
Outperform
Baidu price target raised to $200 from $188 at Oppenheimer
Oppenheimer analyst Jason Helfstein raised his price target for Baidu to $200 from $188 following better Q3 results on margins and management comments suggesting an end to the new compliance process. The analyst remains optimistic on Baidu's long-term competitive position and reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

ZYNE

Zynerba

$22.10

0.27 (1.24%)

07:59
02/24/17
02/24
07:59
02/24/17
07:59
Initiation
Zynerba initiated  »

Zynerba initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

NGVT

Ingevity

$54.35

-2.06 (-3.65%)

07:58
02/24/17
02/24
07:58
02/24/17
07:58
Recommendations
Ingevity analyst commentary  »

Ingevity weakness creates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USM

U.S. Cellular

$44.84

-0.37 (-0.82%)

07:58
02/24/17
02/24
07:58
02/24/17
07:58
Earnings
U.S. Cellular sees FY17 revenue $3.8B-$4B, consensus $4.05B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

BSX

Boston Scientific

$24.48

-0.68 (-2.70%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Recommendations
Boston Scientific analyst commentary  »

Selloff in Boston…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 17

    Mar

  • 04

    May

USM

U.S. Cellular

$44.84

-0.37 (-0.82%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Earnings
U.S. Cellular reports Q4 EPS (7c), consensus (25c) »

Reports Q4 revenue $991M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

BMY

Bristol-Myers

$55.77

0.42 (0.76%)

07:57
02/24/17
02/24
07:57
02/24/17
07:57
Hot Stocks
Bristol-Myers' Abatacept designated as orphan treatment of IIM »

Bristol-Myers'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

  • 17

    Mar

  • 01

    Apr

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:56
02/24/17
02/24
07:56
02/24/17
07:56
Earnings
Telephone and Data sees FY17 revenue $5.015B-$5.265B, consensus $5.29B »

Sees FY17 adjusted EBITDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

JNJ

Johnson & Johnson

$120.90

2.18 (1.84%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Hot Stocks
Janssen's Stelara designated as orphan treatment of pediatric ulcerative colitis »

Janssen's Stelara…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 27

    Feb

  • 09

    Mar

  • 14

    Mar

  • 27

    Mar

NVRO

Nevro

$94.25

-2.26 (-2.34%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Recommendations
Nevro analyst commentary  »

Nevro price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RSPP

RSP Permian

$40.36

-0.55 (-1.34%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Conference/Events
RSP Permian to hold a special shareholder meeting »

Special Shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 28

    Feb

  • 20

    Mar

ETN

Eaton

$72.12

-0.38 (-0.52%)

07:55
02/24/17
02/24
07:55
02/24/17
07:55
Conference/Events
Eaton to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 07

    Mar

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:54
02/24/17
02/24
07:54
02/24/17
07:54
Earnings
Telephone and Data reports Q4 EPS (5c), consensus (5c) »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

TDS

Telephone and Data

$32.72

-0.03 (-0.09%)

07:51
02/24/17
02/24
07:51
02/24/17
07:51
Hot Stocks
Telephone and Data raises quarterly dividend to 15.5c per share »

Payment will be made on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

  • 06

    Mar

TERP

TerraForm Power

$11.40

-0.16 (-1.38%)

07:51
02/24/17
02/24
07:51
02/24/17
07:51
Earnings
TerraForm Power reports Q3 EPS (29c), consensus (16c) »

Reports Q3 revenue $178M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHOO

Steven Madden

07:50
02/24/17
02/24
07:50
02/24/17
07:50
Recommendations
Steven Madden analyst commentary  »

Steven Madden price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

PEG

PSEG

$44.25

-0.02 (-0.05%)

07:49
02/24/17
02/24
07:49
02/24/17
07:49
Earnings
PSEG reports Q4 adjusted EPS 54c, consensus 53c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$136.53

-0.58 (-0.42%)

07:49
02/24/17
02/24
07:49
02/24/17
07:49
Recommendations
Apple analyst commentary  »

Apple average selling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Mar

SPLK

Splunk

$64.90

-0.08 (-0.12%)

07:49
02/24/17
02/24
07:49
02/24/17
07:49
Recommendations
Splunk analyst commentary  »

Splunk should be bought…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

PSO

Pearson

$8.10

0.22 (2.79%)

07:48
02/24/17
02/24
07:48
02/24/17
07:48
Hot Stocks
Pearson to rebase dividend from 2017 onwards »

Pearson said: " As…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSO

Pearson

$8.10

0.22 (2.79%)

07:47
02/24/17
02/24
07:47
02/24/17
07:47
Earnings
Pearson backs 2017 outlook, says early trading in line with expectations »

Pearson said its 2017…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MEOH

Methanex

$50.85

-0.75 (-1.45%)

07:46
02/24/17
02/24
07:46
02/24/17
07:46
Upgrade
Methanex rating change  »

Methanex upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

PSO

Pearson

$8.10

0.22 (2.79%)

07:45
02/24/17
02/24
07:45
02/24/17
07:45
Earnings
Pearson reports FY16 adjusted EPS 58.8p vs. 70.3p last year »

Reports FY16 sales…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEX

Terex

$29.91

-1.5 (-4.78%)

07:44
02/24/17
02/24
07:44
02/24/17
07:44
Initiation
Terex initiated  »

Terex reinstated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Mar

  • 07

    Mar

CERN

Cerner

$55.39

0.02 (0.04%)

07:43
02/24/17
02/24
07:43
02/24/17
07:43
Downgrade
Cerner rating change  »

Cerner downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Mar

RLGY

Realogy

$27.41

0.06 (0.22%)

07:43
02/24/17
02/24
07:43
02/24/17
07:43
Hot Stocks
Realogy announces new $300M share repurchase program »

"Our 2016 results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.